Online inquiry

IVTScrip™ mRNA-Anti-APCS, GSK-2398852(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ7866MR)

This product GTTS-WQ7866MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets APCS gene. The antibody can be applied in AL amyloidosis research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001639.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 325
UniProt ID P02743
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-APCS, GSK-2398852(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ7866MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ2865MR IVTScrip™ mRNA-Anti-ICOS, AMG-570(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA AMG-570
GTTS-WQ2569MR IVTScrip™ mRNA-Anti-IGF1R, AMG 479(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AMG 479
GTTS-WQ2386MR IVTScrip™ mRNA-Anti-HGF, AMG 102(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 102
GTTS-WQ4428MR IVTScrip™ mRNA-Anti-CTLA4, BMS-734016(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-734016
GTTS-WQ4820MR IVTScrip™ mRNA-Anti-CD4, BT-061(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BT-061
GTTS-WQ2889MR IVTScrip™ mRNA-Anti-CCR4, AMG-761(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AMG-761
GTTS-WQ6906MR IVTScrip™ mRNA-Anti-Alkaline phosphatase substitute, ENB-0040(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ENB-0040
GTTS-WQ7011MR IVTScrip™ mRNA-Anti-CSF3R, F-627(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA F-627
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW